23
Participants
Start Date
January 9, 2020
Primary Completion Date
October 5, 2023
Study Completion Date
December 1, 2029
Ocrelizumab
"Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks.~Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg"
Childrens National Health Center, Washington D.C.
Cleveland Clinic, Cleveland
Washington Universtiy school of Medicine, St Louis
University of Colorado Denver Childrens Hospital Rocky Mountain MS Center, Aurora
AOU Policlinico V. Emanuele - P.O G. Rodolico, Catania
Boston Childrens Hospital, Boston
Ospedale Pediatrico Bambino Gesù, Rome
Azienda Ospedaliera Sant'Andrea, Rome
Uniwersyteckie Centrum Kliniczne, Gda?sk
Uniwersytecki Szpital Kliniczny w Poznaniu, Późna
Dzieci?cy Szpital Kliniczny im. Józefa Polikarpa Brudzi?skiego, Warsaw
Instytut Pomnik Centrum Zdrowia Dziecka, Warsaw
Hoffmann-La Roche
INDUSTRY